Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
Can J Cardiol
; 14 Suppl A: 6A-13A, 1998 Apr.
Article
en En
| MEDLINE
| ID: mdl-9594927
ABSTRACT
Evidence supports the idea that substantial benefits may derive from treatments that increase high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein (apo) A-I, HDL2 (or 2b) or the size of HDL particles with, or without, apo A-II. HDL3 appears to be neutral in terms of coronary artery disease risk, and apo A-II appears to be adverse. Because HDL particles serve as antioxidants in vitro, the hypothesis that low HDL-C reflects an antioxidant deficiency state appears tenable. Based on these observations, a three-year angiographic study was proposed and received funding. Enrollment began in January 1995 and was completed in January 1997.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Vitaminas
/
Enfermedad de la Arteria Coronaria
/
Enfermedad Coronaria
/
HDL-Colesterol
/
Revascularización Miocárdica
/
Hipolipemiantes
/
Antioxidantes
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Can J Cardiol
Asunto de la revista:
CARDIOLOGIA
Año:
1998
Tipo del documento:
Article